文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

超声内镜引导射频消融治疗伴担忧特征的分支胰管型IPMN:非手术患者长期结局

Endoscopic ultrasound-guided radiofrequency ablation for intraductal papillary mucinous neoplasms with worrisome features: long-term outcomes in nonsurgical patients (with video).
PubMed 文献 · Gastrointest Endosc · 2026-03-27

技术成功100%,局部控制率98%,无治疗病灶进展为癌,不良事件发生率27%多为轻症腹痛。EUS-RFA对不适合手术的BD-IPMN患者可行、安全且局部控制持久。

要点

  • EUS-RFA对伴WF/HRS的BD-IPMN非手术患者技术成功率达100%,局部控制率98%。
  • 不良事件发生率27%,多为轻度腹痛,术后胰腺炎3例(含1例坏死性胰腺炎),无操作相关死亡。
  • 无治疗病灶进展为癌,但8%患者出现远离治疗囊肿的胰腺癌,需全程监测全胰腺。

核心结论

  • EUS-RFA对不适合手术或拒绝手术的伴WF/HRS的BD-IPMN患者可行、安全,并能实现持久的局部控制。
  • 结果支持EUS-RFA作为经过仔细选择患者的有前景治疗选择,但需更大样本前瞻性研究确认长期肿瘤学获益。

研究设计与样本

  • 单中心回顾性分析2015—2024年前瞻性维护队列中连续接受EUS-RFA的BD-IPMN伴WF/HRS患者。

主要发现

  • 技术成功率为100%。
  • 不良事件发生于27%的操作中,多为轻度腹痛;术后胰腺炎3例,其中1例为坏死性胰腺炎;无操作相关死亡。
  • 局部控制率达98%,17%病灶影像学完全消失,86%病灶缩小;无治疗病灶进展为癌。
  • 全胰腺疾病控制在80%患者中维持;4例(8%)患者出现远离治疗囊肿的胰腺癌。
  • 较小的囊肿尺寸和较少的WF与更好的结局相关。

关键数值与推荐

  • 局部控制定义为WF/HRS消退且治疗病灶无癌发生,本研究中达98%。
  • 全胰腺疾病控制维持率为80%,远处胰腺癌发生率为8%。

临床怎么用

  • 对于伴WF/HRS的BD-IPMN且不适合手术或拒绝手术的患者,可考虑EUS-RFA作为微创替代治疗。
  • 治疗后需继续监测全胰腺,因存在远离治疗部位的胰腺癌风险(8%)。

局限性

  • 需更大规模前瞻性研究细化患者选择标准并确认长期肿瘤学获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) are precancerous cystic lesions. Surgery is advised for high-risk stigmata (HRS) or multiple worrisome features (WFs), but it entails substantial morbidity, and many resections reveal only low-grade dysplasia. EUS-guided radiofrequency ablation (EUS-RFA) is a minimally invasive alternative, yet long-term data are limited. METHODS: We retrospectively analyzed a prospectively maintained cohort of consecutive patients who underwent EUS-RFA for BD-IPMNs with WFs/HRS at a tertiary referral center (2015-2024). Eligible patients were inoperable or declined surgery. Outcomes included technical success, adverse events (AEs), local control (defined as resolution of WFs/HRS with no cancer arising from the treated lesion), radiologic response, and pancreas-wide events. RESULTS: Fifty patients (62 procedures; 58 lesions) were treated. Mean follow-up was 4.1 ± 2.8 years after radiofrequency ablation. Technical success was 100%. AEs occurred in 27% of procedures, mostly mild abdominal pain; postprocedural pancreatitis occurred in 3 patients, including 1 case of necrotizing pancreatitis; there were no procedure-related deaths. Local control was achieved in 98% of lesions; 17% showed complete radiologic disappearance, and 86% decreased in size. No treated lesion progressed to cancer. Pancreas-wide disease control was maintained in 80% of patients; 4 (8%) patients developed pancreatic cancer remote from the treated cyst. Smaller cyst size and fewer WFs were associated with better outcomes. CONCLUSIONS: EUS-RFA is feasible, safe, and provides durable local control of BD-IPMNs with WFs/HRS in patients who are unsuitable for surgery or who decline resection. These results support EUS-RFA as a promising therapeutic option in carefully selected patients. Larger prospective studies are needed to refine selection criteria and confirm long-term oncologic benefits.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Barras J, Lorenzo D, Gasmi M, et al. Endoscopic ultrasound-guided radiofrequency ablation for intraductal papillary mucinous neoplasms with worrisome features: long-term outcomes in nonsurgical patients (with video). Gastrointest Endosc. 2026. PMID: 41903818. doi:10.1016/j.gie.2026.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。